Radiopharm Theranostics Limited (RADX)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Mr. Paul Edward-Alexander Hopper A.S.i.A, B.A (UNSW), FAICD
|
Founder & Executive Chairman | 212.84k | -- | 1956 |
|
Mr. Riccardo Canevari
|
MD, CEO & Director | 1.19M | -- | -- |
|
Dr. Dimitris Voliotis M.D.
|
Chief Medical Officer | 825.43k | -- | 1963 |
|
Mr. Aaron Laurita
|
Chief Financial Officer | -- | -- | -- |
|
Mr. Hitesh Goel
|
Head of Project Management | -- | -- | -- |
|
Mr. Nathan Jong C.A.
|
Joint Company Secretary | -- | -- | -- |
|
Ms. Amritha Sushil
|
Joint Company Secretary | -- | -- | -- |
Radiopharm Theranostics Limited
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 14
Description
Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs in the United States. The company develops RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic. It is also developing RAD301 and RAD302, which are Avß6-Integrin pancreatic diagnostic and therapeutic products; RAD401, a PSA-mAb prostate cancer diagnostic; and RAD402, a PSA-mAb prostate cancer therapeutic. The company was incorporated in 2021 and is based in Carlton, Australia.
Corporate Governance
Upcoming Events
Upcoming Events Information Not Available
